Table 4.
Baseline characteristics of the cyclosporine and tacrolimus subgroups
| Variable | Tacrolimus (n = 197) | Cyclosporine (n = 273) | Probability |
|---|---|---|---|
| Age | 46 ± 12 | 51 ± 13 | <0.001 |
| Male gender % (n) | 53.8 (106) | 62.6 (171) | 0.055 |
| Deceased donor (%) | 66.5 (131) | 66.7 (182) | 0.969 |
| Duration transplant | 2.6 ± 2.6 | 6.9 ± 5.0 | <0.001 |
| Any cardiovascular disease | 22.8 (45) | 30.8 (84) | 0.058 |
| Diabetes mellitus pretreatment | 25.4 (50) | 17.6 (48) | 0.04 |
| New-onset diabetes mellitus | 19.3 (38) | 16.1 (44) | 0.372 |
| EKG left ventricular hypertrophy | 13.3 (26/195) | 22.7 (58/256) | 0.012 |
| Body mass index | 28.4 ± 6.1 | 30.0 ± 6.6 | 0.363 |
| Smoking | 23.9 (47) | 17.9 (48) | 0.116 |
| Systolic BP | 131 ± 17 | 135 ± 17 | 0.043 |
| Diastolic BP | 78 ± 9 | 78 ± 10 | 0.517 |
| Total cholesterol | 4.83 ± 1.02 | 5.40 ± 1.15 | <0.001 |
| LDL | 2.69 ± 0.81 | 2.93 ± 0.93 | <0.001 |
| Albumin | 38 ± 4 | 38 ± 4 | 0.419 |
| Hemoglobin | 132 ± 17 | 129 ± 16 | 0.041 |
| Creatinine clearance | 67 ± 25 | 57 ± 21 | <0.001 |
| Dipstick >negative | 27.7 (54) | 31.0 (83) | 0.447 |
| ASA | 29.4 (58) | 33.7 (92) | 0.33 |
| β-blocker | 50.5 (99) | 49.8 (136) | 0.926 |
| ACEi/ARB | 36.0 (71) | 48.7 (133) | 0.006 |
| Statin | 42.1 (83) | 58.2 (159) | 0.001 |